Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.39 |
| ▸ | GHSR | Q92847 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511094 | 0.94 | GAA (0.43) | GAACYP2D6GHSRKCNH2CYP3A4 | |
| SCHEMBL5508236 | 0.93 | ACHE (0.40) | GAAACHEBCHEAADATRAB9A | |
| SCHEMBL5511672 | 0.90 | ACHE (0.38) | GAACYP2D6KCNH2ACHEBCHE | |
| SCHEMBL5506248 | 0.87 | ACHE (0.51) | GAAACHEBCHEL3MBTL1 | |
| SCHEMBL5508714 | 0.87 | ACHE (0.44) | GAAACHEBCHEAADATL3MBTL1 | |
| SCHEMBL5506377 | 0.84 | ACHE (0.42) | GAAACHEBCHEL3MBTL1HRH3 | |
| SCHEMBL5511760 | 0.82 | ELANE (0.39) | GAACYP3A4DPP4ACHEBCHE | |
| SCHEMBL5510773 | 0.82 | TUBB4A (0.43) | CYP2D6GHSRKCNH2CYP3A4DPP4 | |
| SCHEMBL5512094 | 0.81 | ACHE (0.56) | GAAACHEBCHEL3MBTL1 | |
| SCHEMBL5509751 | 0.77 | ACHE (0.44) | CYP3A4ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521583-B1 | 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO (2,1-B)-QUINAZOLINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-01-10 | — | — | EP | disclosed |
| US-7067519-B2 | 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-06-27 | — | — | US | disclosed |
| EP-1521583-A1 | 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO (2,1-B)-QUINAZOLINONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-13 | — | — | EP | disclosed |
| US-20050009852-A1 | 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates | ACTELION PHARMACEUTICALS, LTD. (CH) | 2005-01-13 | — | — | US | disclosed |
| WO-2004004733-A1 | 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO[2,1-B]-QUINAZOLINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009852-A1 | 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates | HCRTR2, HCRTR1, NPY1R | GAA 2045/4885CYP2D6 277/4885GHSR 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.